Business & Economy
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Source: Business News · Published
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Related stories
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Business News ·
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
Business News ·
UK diesel price tops £2 a litre as G7 countries agree to release 100 million barrels of oil
The £2 threshold was crossed as the group of advanced economies agreed to a substantial release of fuel reserves.
feeds.bbci.co.uk ·
Ford fends off Hyundai to retain No. 3 U.S. sales position in third quarter
Ford on Friday reported a year-over-year sales decline of 6.6% during the third quarter to 507,395 light-duty vehicles.
Business News ·
American starts letting customers mix cash and miles for tickets
American is joining other carriers that allow customers to book with a combination of points and miles.
Business News ·